ImmunoGen Company Profile (NASDAQ:IMGN)

ImmunoGen trades on the NASDAQ under the ticker symbol "IMGN."

ImmunoGen, Inc. (NASDAQ:IMGN) posted its quarterly earnings results on Friday, July, 28th. The company reported ($0.10) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.07. The business had revenue of $39.02 million for the quarter, compared to the consensus estimate of $30.59 million. The company's revenue for the quarter was up 426.6% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.53) EPS. View ImmunoGen's Earnings History.

8 brokers have issued 12 month target prices for ImmunoGen's stock. Their forecasts range from $1.30 to $12.00. On average, they expect ImmunoGen's share price to reach $8.05 in the next twelve months. View Analyst Ratings for ImmunoGen.

Here are some recent quotes from research analysts about ImmunoGen stock:

• 1. Cantor Fitzgerald analysts commented, "IMGN’s speed to market strategy with mirvetuximab soravtansine is intended to advance the drug through the regulatory process by the end of 2020 (FORWARD I), and it is on track." (9/25/2017)
• 2. Cowen and Company analysts commented, "IMGN announced a collaboration agreement with Jazz for the development and." (8/29/2017)
• 3. According to Zacks Investment Research, "ImmunoGen has made significant progress with regard to its lead pipeline candidate, mirvetuximab soravtansine (platinum-resistant ovarian cancer). However, most of the pipeline candidates are in early stages of development and still a long way from entering the market, if at all. Moreover, ImmunoGen has only a limited number of wholly owned candidates in its pipeline. Hence successful development and subsequent approval of its lead candidate, is crucial for growth at ImmunoGen. On the flip side, the company’s collaborations with big healthcare companies not only validate its technology but also provide it with funds in the form of milestone and royalty payments. The company’s shares have outperformed the broader industry so far this year. Notably, estimates have been going down lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/10/2017)

ImmunoGen saw a decline in short interest in September. As of September 15th, there was short interest totalling 12,429,992 shares, a decline of 37.5% from the August 31st total of 19,881,251 shares. Based on an average daily trading volume, of 4,919,562 shares, the days-to-cover ratio is presently 2.5 days. Approximately 14.3% of the shares of the stock are short sold.

Some companies that are related to ImmunoGen include Foundation Medicine (FMI), Biohaven Pharmaceutical Holding Co Ltd (BHVN), Momenta Pharmaceuticals (MNTA), Esperion Therapeutics (ESPR), Genus plc (GNS), Global Blood Therapeutics (GBT), Medpace Holdings (MEDP), Genomic Health (GHDX), Cellectis S.A. (CLLS), Arena Pharmaceuticals (ARNA), Editas Medicine (EDIT), Albany Molecular Research (AMRI), Intellia Therapeutics (NTLA), BeyondSpring (BYSI), Heron Therapeutics (HRTX), TG Therapeutics (TGTX), Enanta Pharmaceuticals (ENTA) and Spectrum Pharmaceuticals (SPPI).

ImmunoGen's management team includes the folowing people:

• Stephen C. McCluski, Independent Chairman of the Board
• Mark J. Enyedy, President, Chief Executive Officer, Director
• David B. Johnston PhD, Chief Financial Officer, Executive Vice President
• Ellie Harrison, Chief Human Resource Officer, Vice President
• Richard J. Gregory Ph.D., Executive Vice President - Research, Chief Scientific Officer
• John M. Lambert Ph.D., Executive Vice President - Distinguished Research Fellow
• Craig Barrows, Vice President, General Counsel, Secretary
• Peter J. Williams, Vice President - Business Development
• Mark A. Goldberg M.D., Independent Director
• Dean Jonathan Mitchell, Independent Director

ImmunoGen's stock is owned by many different of retail and institutional investors. Top institutional shareholders include FMR LLC (6.43%), Redmile Group LLC (5.82%), POLYGON MANAGEMENT LTD. (5.20%), Vanguard Group Inc. (4.87%), State Street Corp (4.62%) and Wells Fargo & Company MN (1.81%). Company insiders that own ImmunoGen stock include Charles Q Morris, Craig Barrows, Daniel M Junius, Dean J Mitchell, John Lambert, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Institutional Ownership Trends for ImmunoGen.

ImmunoGen's stock was sold by a variety of institutional investors in the last quarter, including KBC Group NV, Pinnacle Associates Ltd., Wells Fargo & Company MN, Teachers Advisors LLC, Creative Planning, Swiss National Bank, UBS Asset Management Americas Inc. and Northern Trust Corp. View Insider Buying and Selling for ImmunoGen.

ImmunoGen's stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, State Street Corp, Redmile Group LLC, EAM Investors LLC, Candriam Luxembourg S.C.A., Farallon Capital Management LLC, AXA and Paulson & CO. Inc.. Company insiders that have bought ImmunoGen stock in the last two years include Craig Barrows, Dean J Mitchell, Mark Alan Goldberg, Mark J Enyedy and Richard J Gregory. View Insider Buying and Selling for ImmunoGen.

Shares of ImmunoGen can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of ImmunoGen stock can currently be purchased for approximately $6.70.